




Down-regulation of CK2 correlates with decreased expression levels of DNA
replication minichromosome maintenance protein complex (MCM) genes
Schaefer, Susanne; Doktor, Thomas K; Frederiksen, Sabrina B; Chea, Kathleen; Hlavacova,
Mirka; Bruun, Gitte H; Rabjerg, Maj; Andresen, Brage S; Dominguez, Isabel; Guerra, Barbara
Published in:
Scientific Reports







Publisher's PDF, also known as Version of record
Link to publication from Aalborg University
Citation for published version (APA):
Schaefer, S., Doktor, T. K., Frederiksen, S. B., Chea, K., Hlavacova, M., Bruun, G. H., Rabjerg, M., Andresen, B.
S., Dominguez, I., & Guerra, B. (2019). Down-regulation of CK2 correlates with decreased expression levels of
DNA replication minichromosome maintenance protein complex (MCM) genes. Scientific Reports, 9(1), [14581].
https://doi.org/10.1038/s41598-019-51056-5
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to
the work immediately and investigate your claim.
1Scientific RepoRtS |         (2019) 9:14581  | https://doi.org/10.1038/s41598-019-51056-5
www.nature.com/scientificreports
Down-regulation of CK2α 
correlates with decreased 
expression levels of DnA replication 
minichromosome maintenance 
protein complex (McM) genes
Susanne Schaefer1, thomas K. Doktor1, Sabrina B. frederiksen1, Kathleen chea3, 
Mirka Hlavacova3, Gitte H. Bruun1, Maj Rabjerg2, Brage S. Andresen  1, isabel Dominguez  3 
& Barbara Guerra1
Protein kinase CK2 is a serine/threonine kinase composed of two catalytic subunits (CK2α and/or 
CK2α’) and two regulatory subunits (CK2β). It is implicated in every stage of the cell cycle and in the 
regulation of various intracellular pathways associated with health and disease states. The catalytic 
subunits have similar biochemical activity, however, their functions may differ significantly in cells and 
in vivo. In this regard, homozygous deletion of CK2α leads to embryonic lethality in mid-gestation 
potentially due to severely impaired cell proliferation. To determine the CK2α-dependent molecular 
mechanisms that control cell proliferation, we established a myoblast-derived cell line with inducible 
silencing of CK2α and carried out a comprehensive RNA-Seq analysis of gene expression. We report 
evidence that CK2α depletion causes delayed cell cycle progression through the S-phase and defective 
response to replication stress. Differential gene expression analysis revealed that the down-regulated 
genes were enriched in pathways implicated in cell cycle regulation, DNA replication and DNA damage 
repair. Interestingly, the genes coding for the minichromosome maintenance proteins (MCMs), which 
constitute the core of the replication origin recognition complex, were among the most significantly 
down-regulated genes. These findings were validated in cells and whole mouse embryos. Taken 
together, our study provides new evidence for a critical role of protein kinase CK2 in controlling DNA 
replication initiation and the expression levels of replicative DnA helicases, which ensure maintenance 
of proliferative potential and genome integrity in eukaryotic cells.
Protein kinase CK2 is a serine-threonine kinase with orthologs in all eukaryotes from plants to yeast and mam-
mals1. This enzyme is evolutionarily conserved among species and has been linked to the regulation of intracellu-
lar processes including DNA transcription, protein translation and circadian rhythm and associated with various 
diseases particularly cancer, neurodegenerative disorders and inflammation emerging as a key cellular regulator 
in both health and disease states (reviewed in2–5). In mammals, CK2 can be expressed in the form of tetrameric 
holoenzyme composed of two catalytic (CK2α and/or CK2α’) and two regulatory subunits (CK2β), however, 
accumulating evidence from mouse models and cell lines have revealed functional specialization of the individ-
ual isoforms, challenging the traditional view of CK2 as a stable tetrameric enzyme. In this respect, numerous 
studies have shown that the three proteins may display different subcellular localization and expression pattern 
and levels, and have independent interaction partners (Refs6,7 and reviewed in8,9). In addition, CK2α is required 
for preserving the stability of CK2β by a mechanism involving intermolecular phosphorylation of the latter in the 
N-terminal domain10.
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Data using gene targeting by homologous recombination have significantly strengthened the notion that 
the CK2α and CK2α’ isoforms might be functionally specialized1 and although the corresponding genes are 
highly homologous with approximately 90% sequence identity10 genetic studies have shown that the phenotypic 
response is markedly different in vivo11,12. CK2α is the more abundant catalytic isoform and with broader expres-
sion pattern. CK2α+/− mice have a normal lifespan and no apparent phenotype, while mice lacking CK2α die by 
embryonic day (E) 11.0 and show abnormalities in a number of tissues and organs including the heart and neural 
tube due to diminished cell proliferation and not increased cell death12–14. Conversely, homozygous deletion of 
CK2α’ results in viable mice although the males are affected by oligospermia, which results in infertility11.
CK2 has been shown to positively regulate cell cycle progression in a number of cancer cell lines (reviewed 
in2,15) by interacting and/or phosphorylating cell cycle-regulatory proteins (e.g. p53, p21WAF1/CIP1, PLK1, Chk1, 
Wee1)16–19 and proteins involved in the DNA damage response (e.g. XRCC1, MDC1, DNA-PK and 53BP1)20–24. 
Even though CK2 has been linked to these proteins, to date, there is no clear evidence of this enzyme’s targets in 
non-cancerous cells and in vivo.
In order to identify the CK2α-dependent molecular events controlling cell division on a wide scale, we gen-
erated myoblasts with inducible down-regulation of CK2α and carried out a global gene expression profiling by 
RNA sequencing (RNA-Seq). We provide for the first time in vitro and in vivo evidence showing that lack of CK2α 
negatively affects important components of the DNA replication machinery uncovering a previously uncharacter-
ized role of CK2 in the maintenance of replication fork integrity in eukaryotic cells.
Results
Generation and characterization of a myoblast cell line with inducible down-regulation of CK2α. 
In order to systematically examine the role of CK2α in the control of proliferation in non-cancerous cells, we cre-
ated a myoblast cell line derived from H9c-2 cells with inducible down-regulation of CK2α. Cultured myoblasts 
are one of the models chosen for studying biological processes in vitro. The H9c-2 myoblast cell line isolated 
from ventricular tissue, is currently used as a mimetic for skeletal muscle but it also has the ability to differentiate 
towards a cardiac-like phenotype under appropriate experimental conditions responding similarly to neonatal 
cardiomyocytes to several stimuli25. We transduced H9c-2 myoblast cells with a tGFP-expressing lentiviral-based 
vector designed to express a short-hairpin RNA (shRNA) targeting rat CK2α under the control of doxycy-
cline (Fig. 1a). Because a myoblast cell line with inducible down-regulation of CK2α had not been previously 
described, we first characterized biochemically the newly established cell line (hereafter referred to as H9c2-
CK2α-44). To determine the timing and extent of transduction, H9c2-CK2α-44 cells were analyzed for tGFP 
expression following addition of doxycycline. Cells were harvested at various intervals for up to six days and green 
fluorescence emission was determined by flow cytometry. As indicated in Fig. 1b,c, virtually all the cells were able 
to express tGFP and showed increasing fluorescence signal in a time-dependent fashion indicating the successful 
stable transduction of the target cells. Levels of expression of CK2α were determined by Western blot. Results 
shown in Fig. 1d revealed high intracellular levels of CK2α than CK2α’ in the absence of doxycycline. Incubation 
with doxycycline for up to six days resulted in nearly complete disappearance of CK2α protein, a slight increase 
in the expression of CK2α’ and decreased expression levels of CK2β (Fig. 1e). To support the molecular effects 
of CK2α disappearance on a known intracellular CK2 target protein, we analyzed the phosphorylation status of 
PTEN at S380/T382/38326. Western blot analysis on whole lysate from cells treated as indicated in Fig. 1f revealed 
that the levels of phosphorylation of PTEN were decreased in cells with reduced expression of the individual CK2 
catalytic isoforms as compared to control experiment (Fig. 1f, lanes 2 and 3 vs lane 1). PTEN phosphorylation 
further decreased when CK2α and CK2α’ were simultaneously down-regulated (Fig. 1f, lane 4) suggesting that 
both isoforms contribute to PTEN phosphorylation.
Down-regulation of CK2α interferes with cell cycle progression and cell proliferation. We 
examined the effect of CK2α silencing on the proliferation of H9c2-CK2α-44 cells essentially by three comple-
mentary approaches: i.e. FACS analysis, Western blot and BrdU-based assay. Incubation with doxycycline for 
three and six days, respectively, resulted in marked differences in the cell density as compared to control cells 
(Fig. 2a). Flow cytometry analysis of H9c2-CK2α-44 cells was carried out at various time points after the addi-
tion of doxycycline to determine whether the reported differences resulted from cell cycle perturbation and/or 
enhanced cell death (Fig. 2b). Analysis of DNA content revealed a reproducible and significant slightly increased 
G1 population for up to six days of incubation time with doxycycline as compared to control experiments. The 
fraction of cells in sub-G1, which provides an indicative measurement of cell death, was, however, negligible 
and could not explain the significant decrease in cell density observed in cells with lowered expression of CK2α 
(Fig. 2a). Next, we synchronized cells by serum starvation and looked at their ability to resume the cell cycle after 
adding complete growth medium. As shown in Fig. 2c, cells expressing CK2α resumed proliferation and reached 
the S phase after 12 h from serum deprivation as also confirmed by the analysis of the expression of cyclin E 
which is considered a critical regulator of the G1-S transition (Fig. 2d,27,28). Conversely, cells lacking CK2α did 
not resume the cell cycle at the same pace showing, instead, a delayed progression from G1 to S phase (Fig. 2c,d). 
In support of these results, cellular BrdU incorporation assay carried out with H9c2-CK2α-44 cells showed fewer 
cells in S-phase three days after addition of doxycycline suggesting that down-regulation of CK2α resulted in 
either less efficient or delayed entry into S-phase (Fig. 2e). Analysis of the parental cell line did not show any 
difference on BrdU incorporation under the same experimental conditions indicating that these perturbations of 
the cell cycle could account for the observed slow proliferation rate in cells lacking CK2α.
CK2α silencing results in enhanced sensitivity to replication stress. We hypothesized that delayed 
entry into S-phase could be caused by defective DNA replication initiation in cells with reduced levels of CK2α. 
If so, we anticipated that these cells would become highly sensitive to replication stress induced in the presence 
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Figure 1. Establishment of the doxycycline-regulated H9c2-CK2α-44 cell line with inducible silencing of 
CK2α. (a) H9c-2 cells were transduced with lentiviral particles carrying a SMARTchoice inducible CK2α-
shRNA construct containing a turbo-GFP (tGFP) reporter gene (upper). Expression of CK2α-shRNA is 
induced in the presence of doxycycline (lower). (b) The H9c-2-derived cell line (i.e. H9c2-CK2α-44) stably 
incorporating the construct was analyzed by flow cytometry in the presence of 1 µg/ml doxycycline for up to six 
days. Quantification of green fluorescence emission (tGFP-positive cells) indicative of the efficiency of shRNA 
transcription is shown in the graph. Dashed line indicates the median levels of tGFP expression after two days 
of incubation for both doxycycline-treated (grey peak) and control cells (black peak). Fluorescence-based 
pictures of cells showing increasing expression of tGFP in the presence of doxycycline are shown on the right 
side. Cell nuclei were visualized by Hoechst 33258 staining. (c) Median fluorescence is shown in the dot plot 
in arbitrary units. Vehicle control (CT) at six days is depicted. Two independent experiments were carried out. 
Results from one representative experiment are shown. (d) H9c2-CK2α-44 cells were treated with vehicle (i.e. 
dd water) or with 1 µg/ml doxycycline (Dox) for increasing amounts of time. Whole cell lysates were analyzed 
by Western blot employing a mouse monoclonal antibody against CK2α and CK2α’. β-actin detection served 
as loading control. (e) H9c2-CK2α-44 cells and the parental cell line were harvested after 0, 2 and 3 days of 
treatment with vehicle (−) or 1 µg/ml doxycycline (+) and whole cell lysates were analyzed by Western blot 
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of DNA replication inhibitors. To test this hypothesis, we studied cell cycle progression in response to mild rep-
lication stress in the absence or presence of 0.1 μM aphidicolin for increasing amounts of times. As shown in 
Fig. 3a, treatment with aphidicolin and doxycycline significantly impaired the proliferation of H9c2-CK2α-44 
cells as compared to control cells or cells treated with either compounds alone. Conversely, the proliferation rate 
of the parental cell line was not significantly affected by the treatment with the compounds used either alone or 
in combination (Fig. 3b). Analysis of DNA content by flow cytometry of cells treated with doxycycline revealed a 
slightly but reproducible higher percentage of cells in G1-phase (Fig. 3c). Cells treated with aphidicolin showed 
marginally increased accumulation of cells at the G1-S border, which was expected considering the low con-
centration of aphidicolin employed to induce mild replication stress. Finally, incubation with both compounds 
resulted in accumulation of cells in both G1 and S phases (Fig. 3c). Hence, their accumulation in the early phases 
of the cell cycle at the expense of G2/M may explain lack of proliferation observed following induction of mild 
replication stress.
Global gene expression profiling uncovers a novel role of CK2α in DnA replication initiation. 
To shed light on the mechanisms by which CK2α regulates cell proliferation in myoblasts, we performed a 
global gene expression analysis with RNA isolated from H9c2-CK2α-44 cells left untreated or incubated with 
doxycycline for three days. The transcriptome analysis was also carried out with the parental cell line following 
siRNA-mediated down-regulation of CK2α to exclude off-target effects resulting from particular sites of integra-
tion of lentiviral-based constructs into the genome of the host cells. We performed two independent experiments 
in duplicate obtaining, therefore, four independent replicates for each cell line and condition using the Illumina 
platform. From the 2 × 100 bp paired end Illumina run and after trimming of the raw reads, we generated between 
131.422.420 and 173.796.784 million reads for each of the four conditions. The reads were then mapped and aligned 
to the rat genome version rnor6.0 using STAR version 2.5.0c. On average for the four conditions a total of 95% of 
the reads were mapped and around 70% of the reads were mapped uniquely (Fig. 4a). Furthermore, the quality 
of the data was also confirmed from proper assessment of the fastQC files, which fulfilled all quality controls. 
Gene expression analysis was performed using DEseq2. By comparing the log2 fold-changes of gene expression in 
the two cell lines (i.e. H9c2-CK2α-44 and parental cell lines), we obtained a high correlation between the gener-
ated data (Fig. 4b) indicating that gene expression modifications induced by silencing of CK2α in H9c2-CK2α-44 
cells was not influenced by the integration site of the lentiviral-based construct. Interestingly, we found that the 
down-regulated genes were remarkably more represented within specific cellular pathways than the up-regulated 
genes. Of the 15542 genes identified following analysis of the H9c2-CK2α-44 cells, 1318 genes were found to be 
either up-regulated or down-regulated (8.5%, padj <0.05). In the case of the parental cell line, of the 16435 identi-
fied genes, 1435 were found differentially expressed (8.7%, padj <0.05). H9c2-CK2α-44 and H9c-2 cell lines shared 
95 up-regulated and 339 down-regulated genes, respectively, following silencing of CK2α. From the analysis of 
H9c2-CK2α-44 cells, 548 genes were found up-regulated while 770 resulted down-regulated (Fig. 4c).
To identify the cellular pathways significantly modified in H9c2-CK2α-44 cells and in the parental cell line 
we performed KEGG pathway analysis on the significantly down-regulated genes (Fig. 5). Interestingly, the tran-
scriptome analysis revealed that loss of CK2α had a substantial negative effect on the expression of genes con-
trolling cell cycle (114/115 genes), DNA replication (33 genes) and DNA damage repair [mismatch repair (21 
genes), FA pathway (46 genes), homologous recombination (25 genes), nucleotide excision repair (42 genes) and 
base excision repair (32 genes), Fig. 5 and Table S1]. Within the list of differentially expressed genes we found 
down-regulation of proliferating cell nuclear antigen (PCNA) gene, a number of cyclin-coding genes (Ccna2, 
Ccnab1, Ccne1, Ccne2 and Ccnd2), E2F transcription factor 1 (E2f1) gene and the subunits 1 and 6 of the ori-
gin recognition complex (ORC1, ORC6) genes (Tables 1 and S2). Interestingly, among the most significantly 
down-regulated transcripts we found the minichromosome maintenance protein complex (MCM2-7) genes and 
those coding for DNA-directed polymerase epsilon, delta 1, alpha 2, delta 2, epsilon 2 (Pole, Pold1, Pola2, Pold2, 
Pole2, Table 1). Finally and as predicted, CK2α transcripts were among those most significantly down-regulated 
(log2 Fold-change −1.67791, padj 4.90981E-39) while CK2α’ and CK2β transcripts, were not found significantly 
changed (results not shown). To the best of our knowledge, a cross-talk between CK2 and MCM proteins has 
never been reported before. Numerous studies have shown that these proteins form pre-replication (pre-RCs) 
complexes, also known as “origin licensing” that allow binding of DNA polymerases and other factors to chro-
matin to start DNA replication during the G1-phase29–32. Since their reduced expression levels in cells confers 
hypersensitivity to replication stress33, we decided to further investigate them.
CK2α down-regulation correlates with decreased McMs levels in vitro and in vivo. Using qPCR 
we validated the expression of eight genes (i.e. MCM2-7, Polε and Polδ1, Fig. 6) in cells untreated or incubated 
employing the indicated antibodies. β-actin detection served as loading control. (f) H9c2-CK2α-44 cells were 
incubated with 1 µg/ml doxycycline for three days, transfected with scr-siRNA and CK2α’-siRNA for three 
days, respectively, as indicated in the figure. Last lane refers to cells treated with doxycycline and transfected 
with CK2α’-siRNA for three days. Whole cell lysates were analyzed by Western blot employing the indicated 
antibodies. All experiments were performed three times obtaining similar results; one Western blot experiment 
of three is shown. Abbreviations: LTR: 5’ Long Terminal Repeat; Ψ: Psi packaging sequence; RRE: Rev response 
element; PTRE3G: Inducible promoter with tetracycline response elements; PmCMV: SMARTchoice promoter; 
PuroR: Puromycin resistance; 2a: Self-cleaving peptide; Tet-On 3G: Doxycycline-regulated transactivator 
protein; WPRE: Woodchuck hepatitis post-transcriptional regulatory element; 3’SIN LTR: 3’ Self-inactivating 
long terminal repeat.
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Figure 2. Down-regulation of CK2α perturbs G1/S cell cycle transition dynamics. (a) H9c2-CK2α-44 cells 
were treated with vehicle (CT) or doxycycline for three days and six days, respectively. Phase contrast images 
were taken at 50x magnification. (b) Cells were incubated with vehicle or 1 μg/ml doxycycline for up to six days 
as indicated in the figure. Cell cycle analysis was performed following propidium iodide staining. Amount 
of cells in the various phases of the cell cycle are expressed in percentage. *P < 0.05 with respect to control 
experiment. Figure shows the results of three independent experiments. (c) Cells were synchronized by serum 
starvation for 48 h in the absence or presence of doxycycline and harvested at the indicated time points after 
release from starvation. Cell synchronization was confirmed by flow cytometry analysis. The experiment was 
repeated three times obtaining similar results. (d) Western blot analysis of whole lysate from cells treated as 
indicated in (c) was carried out employing the indicated antibodies. Experiments were repeated three times 
obtaining similar results. One representative experiment is shown. (e) H9c-2 and H9c2-CK2α-44 cells left 
untreated or incubated with 1 µg/ml doxycycline for three days were labeled with BrdU during the last eight 
hours of incubation time. Detection of fixed cells was carried out employing an anti-BrdU antibody coupled to 
horseradish peroxidase. Colorimetric reactions were quantified by measuring the absorbance at 450 nm. Values 
are shown in arbitrary units as average of six replicates +/− STDEV, *P < 0.00001 with respect to control (i.e. 
cells treated with vehicle). Experiments were repeated twice obtaining similar results.
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with doxycycline for three days (shRNA qPCR1). This analysis confirmed down-regulation of the aforemen-
tioned genes. qPCR analysis in cells incubated with doxycycline for six days (shRNA qPCR2) showed reduced 
down-regulation of six (i.e. MCM2, 3, 4, 6, 7 and Polε) of the eight genes analyzed suggesting that some adapta-
tion might have occurred.
Figure 3. Analysis of cell proliferation following induction of mild DNA replication stress. (a) H9c2-CK2α-44 
incubated with 1 µg/ml doxycycline for three days were subsequently re-seeded and treated with 0.1 µM 
aphidicolin (Aphi) for increasing amounts of time as indicated in the figure. Control experiments (CT) 
refer to cells grown in the presence of 0.1% DMSO for up to five days. Cell proliferation was determined by 
hemocytometer counting. Experiments were carried out three times in triplicates obtaining similar results. 
Results of one representative experiment are shown +/− STDEV, *P < 0.05, **P < 0.005. (b) Comparison 
between H9c2-CK2α-44 and H9c-2 cells with respect to proliferation efficiency. Cells were treated essentially as 
described in (a) for the indicated times. Mean values+/− STDEV of one representative experiment out of three 
is shown. *P < 0.05, **P < 0.0005 with respect to CT, #P < 0.01. (c) H9c2-CK2α-44 cells left untreated or treated 
with 1 µg/ml doxycycline for three days were co-treated with 0.1% DMSO or 0.1 µM aphidicolin for additional 
five days. Cells were analyzed by flow cytometry following propidium iodide staining (PI) and events were 
quantified and expressed in percentage.
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Next, we determined whether down-regulation of the MCM genes correlated with decreased expression levels 
of their coded proteins. For this, we analyzed whole lysates from cells treated with vehicle or doxycycline for three 
days. Results shown in Fig. 7a confirmed that silencing of CK2α results in decreased expression of MCM proteins 
with respect to control experiments.
In vivo validation of gene expression variability of two members of the MCM protein family, namely MCM3 
and MCM4, was investigated in tissues of WT and CK2α-knockout embryos i.e.: the hearts (Fig. 7b,c) and 
somites at E10.5 (Fig. 7d,e). It was reported that a variety of defects in the heart at this developmental stage are 
probably responsible for the embryonic lethality observed in mice lacking CK2α12, therefore, we included the car-
diac tissue in the analysis. In hearts, MCM3 and MCM4 specific signal was strongly detected in the cell nucleus. 
Negative controls for MCM4 showed some cytoplasmic background signal both in the myocardial wall and the 
trabeculae (Fig. S1a). We only analyzed the myocardial cells in non-trabecular myocardium, as the trabecular 
myocardium in CK2α−/− embryos is less developed than in the WT heart. Since MCM3 and MCM4 staining 
showed heterogeneous levels of fluorescence in WT hearts, we quantified separately cells emitting high and low 
fluorescence levels. Bar-graphs show a statistically significant lower number of cells emitting high intensity fluo-
rescence in CK2α−/− E10.5 myocardium as compared to WT myocardium (Fig. 7b,c). In somites, MCM3 and 
MCM4 specific signal was strongly detected in the cell nucleus (Fig. 7d,e) while negative controls showed little 
background signal (Fig. S1b). Significant differences in the expression of MCM3 and MCM4 could be detected 
in WT and KO somites, respectively, suggesting that loss of CK2α affects MCM protein levels in vivo during early 
mouse development.
Figure 4. Expression analysis of RNA seq data using DESeq2. (a) Sequencing statistics showing total number 
of reads and the percentage of mapped, uniquely mapped and multi mapped reads for the CK2α-siRNA 
and CK2α-shRNA samples. (b) Bar plot showing the percentage of significantly differentiated genes for the 
CK2α-siRNA and CK2α-shRNA samples, respectively. The percentage of up- and down-regulated genes is also 
displayed. (c) Venn Diagrams of the overlap of the significant differentiated genes between the CK2α-siRNA 
and CK2α-shRNA treated cells [P-value (padj) <0.05].
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Discussion
There is ample evidence showing that CK2α plays an important role in the regulation of cell division. In this study, 
we aimed at identifying potential novel molecular mechanisms controlling cell proliferation in non-cancerous 
cells mediated by CK2α. We show here for the first time that down-regulation of CK2α leads to a significant 
reduction in the expression levels of components of the MCM complex suggesting that MCM proteins could be 
Figure 5. Genome-wide expression analysis reveals unique signatures in cells with reduced expression of 
CK2α. (a) KEGG pathway analysis of H9c2-CK2α-44 cells left untreated or incubated with 1 µg/ml doxycycline 
for three days (upper bar-plot) and (b) of the parental cell line (i.e. H9c-2 cell line) transfected with scramble 
siRNA (scr-siRNA) or siRNA directed against CK2α (CK2α-siRNA, lower bar-plot) for three days following 
global transcription analysis by RNA-Seq. Bar-plots show enriched pathways with respect to the number of 
significantly down-regulated genes within each pathway relative to controls. Panels to the right display volcano 
plots showing log10 of P-values against log2 Fold-change of gene expression. Dots above dashed line refer to 
genes with an adjusted P-value (padj) ≤0.1.
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responsible, at least in part, for the lowered proliferation rate observed in cells and in vivo. The minichromosome 
maintenance complex is a family of structurally related proteins with replicative helicase activity highly conserved 
from yeast to man that are required for cell proliferation, migration and invasion34–36. Mutations in individual 
MCMs have been shown to play a critical role in DNA replication initiation and result in embryonic death, 
growth retardation and limited fetal erythropoiesis37–40.
Reduced levels of CK2α resulted in decreased proliferation rate in H9c2-CK2α-44 cells (Fig. 2). Similar results 
were obtained when the mitotic index in CK2α−/− embryo hearts was compared to the one in WT embryos 
(Suppl. Fig. S2). Our data on WT embryonic heart proliferation fits well with previous reports showing that in WT 
embryos, OFT myocardium has the lowest proliferation rate of whole heart myocardium, and that proliferation 
rates diminish from E9.5 to E10 in the different heart regions41,42. Reduced proliferation was, however, not accom-
panied by a significant increase in cell death both in vitro (Fig. 2b) and in vivo (Table S3) suggesting that decreased 
proliferation rate may explain, at least in part, the growth defects observed in the CK2α−/− embryo heart.
Impaired expression of CK2α caused a reproducible slight increase in the G1/S cell population (Fig. 2). We 
show here for the first time that DNA replication and DNA damage pathways are significantly down-regulated 
in CK2α-silenced myoblasts. Specifically, the expression of MCMs was reduced at both mRNA and protein lev-









ENSRNOG00000003703 Mcm6 minichromosome maintenance complex component 6 [Source:RGD Symbol;Acc:61967] −0.75714 1.66E-43 1.08E-40 −0.68699 4.71E-21 1.65E-18
ENSRNOG00000014336 Mcm5 minichromosome maintenance complex component 5 [Source:RGD Symbol;Acc:1306616] −0.87782 3.11E-32 1.12E-29 −0.9622 2.63E-26 1.60E-23
ENSRNOG00000001349 Mcm7 minichromosome maintenance complex component 7 [Source:RGD Symbol;Acc:1303018] −0.57298 7.30E-25 1.64E-22 −0.43775 5.24E-09 3.14E-07
ENSRNOG00000037449 Polε polymerase (DNA directed), epsilon, catalytic subunit [Source:RGD Symbol;Acc:1594540] −0.62312 7.46E-24 1.51E-21 −0.63192 5.45E-09 3.25E-07
ENSRNOG00000016316 Mcm2 minichromosome maintenance complex component 2 [Source:RGD Symbol;Acc:1305577] −0.54058 1.12E-21 2.01E-19 −0.5083 1.97E-10 1.53E-08
ENSRNOG00000001833 Mcm4 minichromosome maintenance complex component 4 [Source:RGD Symbol;Acc:3060] −0.59195 3.17E-21 5.42E-19 −0.63094 6.89E-19 1.83E-16
ENSRNOG00000012543 Mcm3 minichromosome maintenance complex component 3 [Source:RGD Symbol;Acc:1305168] −0.64377 6.62E-21 1.09E-18 −0.71333 1.32E-17 2.75E-15
ENSRNOG00000019681 Pol δ1 polymerase (DNA directed), delta 1, catalytic subunit [Source:RGD Symbol;Acc:621839] −0.70705 3.82E-19 5.40E-17 −0.5002 4.26E-07 1.70E-05
ENSRNOG00000031993 Prim1 primase, DNA, polypeptide 1 [Source:RGD Symbol;Acc:621380] −0.50871 4.28E-18 5.49E-16 −0.37632 1.46E-06 5.24E-05
ENSRNOG00000021264 Pcna proliferating cell nuclear antigen [Source:RGD Symbol;Acc:3269] −0.36135 5.93E-13 5.20E-11 −0.45828 4.36E-11 3.79E-09
ENSRNOG00000020531 Fen1 flap structure-specific endonuclease 1 [Source:RGD Symbol;Acc:621821] −0.54247 7.06E-13 6.06E-11 −0.43085 2.10E-06 7.15E-05
ENSRNOG00000001134 Rfc5 replication factor C (activator 1) 5 [Source:RGD Symbol;Acc:1309280] −0.50983 8.06E-11 5.52E-09 −0.28927 0.001611 0.022343
ENSRNOG00000001088 Rfc3 replication factor C (activator 1) 3 [Source:RGD Symbol;Acc:1306832] −0.43253 1.03E-09 6.11E-08 −0.03864 0.707713 0.916089
ENSRNOG00000014193 Lig1 ligase I, DNA, ATP-dependent [Source:RGD Symbol;Acc:621424] −0.59388 1.37E-09 8.01E-08 −0.43153 0.000422 0.007455
ENSRNOG00000003123 Rpa1 replication protein A1 [Source:RGD Symbol;Acc:1307376] −0.3821 1.82E-08 9.02E-07 −0.30221 0.000893 0.013954
ENSRNOG00000020906 Polα2 polymerase (DNA directed), alpha 2, accessory subunit [Source:RGD Symbol;Acc:621817] −0.41512 2.99E-08 1.43E-06 −0.43507 4.48E-06 0.000143
ENSRNOG00000001457 Rfc2 replication factor C (activator 1) 2 [Source:RGD Symbol;Acc:621198] −0.40817 4.06E-08 1.91E-06 −0.3773 1.90E-05 0.000517
ENSRNOG00000013005 Rpa2 replication protein A2 [Source:RGD Symbol;Acc:619714] −0.46473 6.44E-07 2.44E-05 −0.43804 0.000576 0.009691
ENSRNOG00000014098 Polδ2 polymerase (DNA directed), delta 2, accessory subunit [Source:RGD Symbol;Acc:1304954] −0.41421 1.17E-06 4.06E-05 −0.32712 0.002745 0.034025
ENSRNOG00000001816 Rfc4 replication factor C (activator 1) 4 [Source:RGD Symbol;Acc:1310142] −0.35667 9.75E-05 0.002146 −0.36891 0.000243 0.004763
ENSRNOG00000020700 Rnaseh2c ribonuclease H2, subunit C [Source:RGD Symbol;Acc:2319141] −0.37524 0.000125 0.00266 −0.37188 0.000284 0.005461
ENSRNOG00000012486 Prim2 primase, DNA, polypeptide 2 [Source:RGD Symbol;Acc:631433] −0.30848 0.000168 0.003453 0.009264 0.920424 0.981675
ENSRNOG00000004242 Polε2 polymerase (DNA directed), epsilon 2, accessory subunit [Source:RGD Symbol;Acc:1311962] −0.42936 0.000501 0.008671 −0.48842 0.002781 0.034413
Table 1. Significantly differentially expressed genes involved in DNA replication following down-regulation of 
CK2α.
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Figure 6. Down-regulation of CK2α leads to decreased expression of genes essential for initiation of DNA 
replication. H9c2-CK2α-44 cells were left untreated or treated with 1 µg/ml doxycycline for three (shRNA RNA-
Seq, shRNA qPCR1) or six (shRNA qPCR2) days while the parental cell line was transfected with CK2α-siRNA 
for three days (siRNA RNA-Seq). Total RNA was isolated and either analyzed by Illumina TrueSeq sequencing 
(RNA-Seq) or used for quantitative reverse transcription PCR (RT-qPCR). Graphs show log2 Fold-change in 
the expression of the indicated genes from cells with reduced CK2α levels relative to control cells, respectively. 
As a comparison, each graph shows results obtained by both RNA-Seq and qPCR, respectively. *P < 0.01, 
**P < 0.001 with respect to vehicle-treated cells. RNA-Seq experiments were carried out twice in duplicates; 
qPCR experiments were performed three times in triplicates. Average values are shown +/− STDEV.
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Figure 7. Down-regulation of gene transcripts correlates with lowered expression of the corresponding MCM 
proteins in CK2α-depleted cells and CK2α−/− mouse embryo hearts and somites. (a) H9c2-CK2α-44 cells 
were treated with 1 µg/ml doxycycline for three days and whole cell lysates were employed for the detection 
of MCM proteins by Western blot as indicated in the figure. β-actin detection was used as loading control. 
(b) MCM3 and MCM4 immunofluorescence staining in heart sections of WT (+/+) and CK2α−/− (−/−) 
embryos at E10.5 (34 somite pairs). Photographs were taken at 20x magnification. Fluorescent images were 
pseudo-colored and show MCM proteins staining (nuclear, green). Lines mark approximately the area where 
cells were counted (non-trabecular myocardium). (c) Bar-graph showing in percentage the ratio of MCM 
positive cells/total number of cells in the myocardium, and the percentage of cells showing high and low 
stain intensity in the myocardium, respectively. Two to three sections each from two pairs of E10.5 WT and 
CK2α−/− embryos were analyzed. Represented values are mean +/− STDEV. Asterisks denote statistical 
significance: *P ≤ 0.05, **P ≤ 0.005. Abbreviations: A (atria); myo (non-trabecular myocardium); tb (trabecular 
myocardium). (d) Immunohistochemistry analysis of whole mouse embryo somites (E10.5) showing detection 
of MCM3 and MCM4 (nuclear, red signal), respectively. Photos were taken at 20x magnification and pseudo-
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proliferating at a slower pace, accumulating in G1 phase and becoming hypersensitive to replication stress33. 
Accordingly, it is plausible that the increase in the G1/S phase population in CK2α-silenced myoblasts accompa-
nied by enhanced sensitivity to replication stress is due to decreased MCMs expression levels.
It has been shown that mice hemizygous for the individual MCM helicases show compromised stability of 
the entire hexameric complex, cell proliferation defects and elevated micronuclei frequencies associated with 
genomic instability (GIN43,). The analysis of CK2α−/− embryo hearts revealed a drastic impairment of cell pro-
liferation, however, it did not show increased GIN (data not shown). It is possible that a certain threshold level of 
expression of the MCM helicases might be necessary to cause GIN and/or that the CK2α−/− embryos do not live 
long enough to accumulate chromosomal aberrations.
A strength of this work is that we used four biological replicates for the RNA-Seq analysis, and we obtained 
reproducible data on proliferation rates, cell cycle aberrations and MCM expression levels both in vivo and with 
cell lines. Part of the work has been carried-out with a clonal cell line for which the risk of clonal selectivity cannot 
be underestimated. However, results obtained with knockout mice (Fig. 7) and siRNA-treated cells (results not 
shown) corroborate the findings obtained with the H9c2-CK2α-44 cells.
We observed a slight increase in CK2α’ expression levels in myoblasts depleted of CK2α (Fig. 1d). It is con-
ceivable that the residual CK2 activity, due to the expression of CK2α’, can make up for the absence of CK2α. A 
compensatory mechanism is plausible since CK2α may compensate for the lack of CK2α’ in mice11. This increase 
in CK2α’ is similar to what has been reported in studies with mouse embryo fibroblasts (MEFs44), and in contrast 
to the lack of increase seen in the CK2α−/− mice13. This suggests that a compensatory mechanism might occur 
in primary cells and cell lines to preserve a certain level of CK2 kinase activity necessary for the in vitro survival 
of the cells which grow in the absence of the endogenous extracellular matrix to which cells do attach in vivo.
In line to what we and others have previously observed in small interfering RNA and gene knock-out stud-
ies13,19,22,44 cells expressing reduced amounts of CK2α also displayed reduced levels of CK2β suggesting that the 
contribution of the latter to the reported effects needs to be addressed in the future. Based on this, we also antici-
pate that a complete absence of CK2 kinase activity (i.e. double CK2α- and CK2α’-ablated mice) will have a more 
profound effect on cell proliferation, and experiments to test this hypothesis are under way.
Taking all these together, our data uncover a novel role of CK2α in the regulation of chromosomal DNA repli-
cation initiation, and propose that MCM helicases deregulation could be an important contributor to the observed 
reduction in cell proliferation in CK2α-deficient cells. We cannot, however, exclude that post-translational modi-
fications of CK2α target proteins and/or additional genes identified in our genome wide expression analysis could 
contribute to the regulation of cell division.
The down-regulation of CK2α was achieved with the transduction of shRNA constructs and the transfection 
of small interfering RNAs, respectively. We found that the overlap of the up- or down-regulated genes in both 
systems was not significantly high, however, irrespective of the strategy pursued, we observed that a large number 
of significantly down-regulated transcripts were in common between the two systems. In this respect, although 
the goal is the same (i.e. the down-regulation of CK2α), the way this result is obtained differs with the two 
approaches. The siRNA-mediated approach involves transfection of a certain number of cells and is dependent on 
the variable efficiency of siRNA up-take. The lentivirus shRNA-knockdown system should, theoretically, affect all 
cells with respect to the silencing of a specific gene product. In the siRNA-based method, a certain amount of cells 
did not take up the siRNA molecules consequently; CK2α was not down-regulated in all cells. Because of this, one 
could not expect a perfect overlapping of the results obtained with the two systems emphasizing the importance 
to apply different approaches and validate significant results as we have performed in this study. Our global anal-
ysis of gene expression identified 770 significantly down-regulated genes (Fig. 4) including not only genes coding 
for proteins regulating DNA synthesis or DNA replication initiation but also for proteins directly regulating cell 
cycle phase transitions such as cyclin-dependent kinases and cyclin proteins. Furthermore, we cannot rule out 
that the decreased proliferation rate seen in cells depleted of CK2α might result from induction of the differenti-
ation program. In this respect, Kankeu et al., carried out a proteomic analysis monitoring the changes in protein 
expression upon differentiation of cardiac myoblasts into cardiomyocyte-like cells and reported evidence that the 
proteins forming the MCM complex are significantly down-regulated in the differentiated cells45.
Future experiments should address the impact of miss-regulation or destabilization of the MCM complex 
and the mechanisms of reduced expression levels of MCMs in cells lacking CK2α. This is important, since muta-
tions in MCMs are responsible for a number of diseases, including cancer, and malformations29,46,47. It will also 
be essential to perform rescue experiments with combinations of the MCM genes to address the importance of 
MCM proteins with respect to cell proliferation in vivo in the context of CK2α deregulation. Finally, it will also 
be important to generate tissue-specific CK2α knockout mice to further elucidate the function of this enzyme 
in different organs and define the pathways that lead to MCM deregulation. This knowledge will be pivotal for 
progressing our understanding of the functional specialization of protein kinase CK2α during embryonic devel-
opment and in adulthood.
Methods
cell culture and treatments. The myoblast cell line H9c-2 derived from embryonic rat myocardium was 
purchased from the American Type Culture Collection (ATCC, Rockville, MD, USA) and cultivated at 37 °C 
under a 5% CO2 atmosphere in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen, Taastrup, Denmark) 
colored. (e) Bar-graph showing in percentage the number of MCM positive cells/total number of cells in the 
embryos. Three to five sections each from three pairs of E10.5 WT and CK2α−/− embryos were analyzed. 
Represented values are mean +/− STDEV, *P ≤ 0.0005, **P ≤ 0.05. Abbreviations: so, somite.
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supplemented with 10% fetal bovine serum (FBS, Biochrom AG, Berlin, Germany). H9c-2 cells were passaged 
before reaching confluence following guidelines to prevent their differentiation. Cells were treated with aphidi-
colin and doxycycline as indicated in the figure legends (both reagents from Sigma-Aldrich, Brøndby, Denmark). 
Down-regulation of protein expression was carried out by RNA interference as previously described24. Sets of four 
small interfering RNA duplexes (ON-TARGET plus SMART pools, Dharmacon, Lafayette, CO, USA) directed 
against CK2α and CK2α’, respectively, were used. Synchronization of cells at G0/G1 was obtained by growing 
them in the presence of 0.1% serum for 48 h. After that, the cell cycle was resumed by adding complete growth 
medium and cells were harvested at different time points as indicated in the figure.
Gene expression silencing in H9c-2 myoblasts. The establishment of a cell line expressing shRNA 
for the inducible down-regulation of CK2α under the control of doxycycline was carried out with the Thermo 
Scientific SMARTchoice inducible shRNA kit following the manufacturer’s instructions (Thermo Scientific, 
Rockford, IL, USA). The SMARTchoice inducible shRNA vector consists of an inducible promoter with tetracy-
cline response element (PTRE3G), activated by the Tet-On 3G protein in the presence of doxycycline (Dox). The 
SMARTvector contains a turbo-GFP (tGFP) reporter gene and a universal scaffold carrying shRNA directed 
against the CK2α sequence GAA.TTA.GAT.CCA.CGT.TTCA. Initially, general transduction conditions and the 
functional titer of viral particles were optimized, according to the manufacturer’s recommendations. Cells were 
treated with optimal viral titer in transduction medium containing 10% serum and 10 µg/ml polybrene for 20 h 
followed by addition of normal growth medium for further 24 h. Transduced cells were selected with 0.3 µg/ml 
puromycin for three days, re-seeded as single cells and allowed to grow until each clone contained 30 to 40 cells. 
The clones were analyzed by Western blot for the efficient down-regulation of CK2α following treatment with 
1 µg/ml doxycycline (Dox). Analysis of green fluorescence-emitting cells was done on a FACSCalibur flow cytom-
eter and data acquisition was carried out with Cell Quest Pro Analysis software (BD Biosciences, Franklin Lakes, 
New Jersey, USA). Cell pictures were taken with a Leica DMRBE fluorescence microscope equipped with a DFC 
420 C camera and Leica Application Suite V 3.3.0 software (Leica Microsystem, Wetzler, Germany).
Preparation of whole cell lysate, Western blot analysis and antibodies. Cells were harvested 
and further processed for Western blot analysis as previously described19. The following primary antibodies 
were employed: mouse monoclonal anti-β-actin (Sigma-Aldrich); goat polyclonal anti-MCM3 and goat poly-
clonal anti-MCM6 (all from Santa Cruz Biotechnology, Heidelberg, Germany); rabbit monoclonal anti-cyclin 
E1, rabbit monoclonal anti-MCM2, rabbit monoclonal anti-MCM4, rabbit monoclonal anti-MCM7 and rab-
bit polyclonal anti-P-PTEN (S380/T382/383, all from Cell Signalling Technology, MA, USA); rabbit polyclonal 
anti-PTEN (Upstate, Lake Placid, NY, USA). Rabbit polyclonal anti-CK2α’ was obtained by immunizing rabbits 
with a specific peptide sequence of human CK2α’ (i.e. SQPCADNAVLSSGTAAR). Rabbit polyclonal anti-CK2α 
was obtained by immunizing rabbits against the human full-length protein sequence. Mouse monoclonal 
anti-CK2α/α’ and mouse monoclonal CK2β were from KinaseDetect Aps, Odense, Denmark.
Cell cycle analysis. Cell cycle analysis and determination of cell death were carried out by propidium iodide 
staining and flow cytometry essentially as previously described22. The analysis of cells was carried out with a 
FACSCalibur flow cytometer (BD Biosciences). Acquired data were processed by Cell Quest Pro Analysis soft-
ware (BD Biosciences). For each measurement, 10,000 events were analyzed. Flow cytometry of trypsin-digested 
mouse embryo cells was performed as described in48. Cells were analyzed using a FACScan flow cytometer (BD 
Biosciences) and data were processed using Cell Quest Pro analysis software (BD Biosciences).
Determination of cell proliferation. Cell proliferation was determined using the BrdU Cell prolifera-
tion Assay (Merck-Millipore, Hellerup, Denmark) following the manufacturer’s instructions. In brief, cells were 
incubated with BrdU for 8 h. After fixation and denaturation, cells were labeled with anti-BrdU antibody for 1 h 
and subsequently with goat anti-mouse IgG HRP-conjugated for 30 min. Conjugates were visualized by adding 
HRP substrate solution. Absorbance was measured using a spectrofotometric plate reader at dual wavelengths of 
450–595 nm. Alternatively, cells were harvested by trypsinization and counted every 24 h for up to 144 h with a 
Neubauer improved counting chamber.
RNA-Seq library preparation, sequencing and data analysis. Total RNA from cells was extracted 
using Isol-RNA lysis reagent (AH Diagnostics, Aarhus, Denmark) and chloroform followed by precipitation 
in isopropanol. RNA concentration, purity and integrity were analyzed applying Nanodrop and Agilent 2100 
Bioanalyzer RNA 6000 nano kit (Agilent Technologies, Inc., Santa Clara, CA, USA). Only RNA with RIN ≥8.0 
and a 28 s/18 s ratio of approx. 1.8 was used for sample preparation. Processing of 500 ng RNA samples for library 
construction was essentially carried out as described in49 using the TruSeq Total RNA LT Sample Prep kit, Set A 
(Illumina) and following the manufacturer’s instructions (Illumina TruSeq Stranded Total RNA sample prepara-
tion guide). Amplified cDNA libraries were validated in regard to size by Agilent 2100 Bioanalyzer using a DNA 
1000 kit from Agilent Technologies and concentration by qPCR using the KaPa Library quantification Kits (KaPa 
Biosystems, Wilmington, MA, USA). 15 pM denatured libraries were loaded on the flow cell for cluster formation 
by bridge amplification cycles followed by paired-end 100 bp sequencing on an Illumina HiSeq1500. For data 
analysis, samples were first trimmed to remove TruSeq adapters using cutadapt50 and, subsequently, mapped to 
the rat genome assembly version rnor6 using STAR51 version 2.5.0c with junction annotation from Ensembl ver 
8452. Subsequently, gene counts were obtained using the same Ensembl reference and HTSeq53, and gene expres-
sion analyzed with DESeq254 using cqn55 derived normalization factors. Pathway analysis was performed using 
GAGE56.
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qPCR analysis. Preparation of whole RNA samples from cultured cells was carried out by phenol-chloroform 
extraction and subsequent silica-membrane-based purification according to the miRNeasy Mini handbook from 
QIAGEN (Hilden, Germany). RNA concentration and quality was determined by Nanodrop measurements and 
RNA integrity was assured by a bioanalyzer. cDNA was prepared using the high capacity cDNA reverse tran-
scription kit from Life Technologies (Invitrogen). Each cDNA sample (20 ng) was used in triplicates as template 
for reactions using Fast Start Essential DNA Green Master (2×, Roche, Mannheim, Germany). The qPCR was 
performed in a Light Cycler LC480 (Roche): 1 cycle at 95 °C/5 min followed by 45 cycles at 95 °C/10 s, 60 °C/10 s, 
72 °C/10 s. Primers used for qPCR (IDT, Leuven, Belgium) were designed to cover two exons thereby eliminat-
ing the risk of DNA contamination being amplified (Table S4). Threshold values were determined by the Light 
Cycler software (LCS480 1.5.1.62 SP1). Each qPCR assay included a no-template control. The specificity of each 
amplification was analyzed by melting curve analysis. Quantification cycle (Cq) was determined for each sample 
and was normalized (ΔCT) to the reference genes vimentin and chaperonin containing TCP1 subunit 2 (cct2). 
Reference genes were chosen based on their observed stability across conditions in the RNA-seq experiments. 
Fold-change of gene expression was calculated with the ΔΔCT method including the equation ΔΔCT = ΔCT 
(experimental sample group) − ΔCT (control group), and the fold-change was calculated based on ΔΔCT with 
2−ΔΔCT. Significance was ascertained by the two-tailed Student’s t-test.
CK2α−/− mice and embryos isolation and processing. Mouse experiments were approved by the 
Boston University Medical Center Institutional Animal Care and Use Committee (IACUC) and performed in 
accordance with relevant guidelines and regulations. The CK2α−/− mice generated through a targeted mutation 
(Csnk2α1tm1Dcs12,) were bred, and embryos genotyped by PCR using yolk sac DNA as described in12. Timed mat-
ing was set by interbreeding CK2α+/− pairs and the morning on which a vaginal plug was observed in the female 
set as embryonic day E0.5. Embryos and hearts were isolated in cold PBS, and when required, hearts were excised 
using micro-scissors and forceps. Embryos and isolated hearts were then snap frozen on dry ice and stored at 
−80 °C for molecular and biochemical studies. For histological and immunological analysis, freshly dissected 
embryos were collected, washed in PBS and fixed at 4 °C with 4% paraformaldehyde in PBS. For histology and 
immunofluorescence (IF) in sections, embryos were dehydrated, embedded and sectioned57. For whole-mount IF 
(WIF), embryos were washed in PBS and stored in 70% ethanol at 4 °C. To obtain reliable results somite-matched 
CK2α−/− and WT embryos were compared in the performed analyses.
Macroscopic and histological analyses. The cardiac phenotype was analyzed from freshly dissected 
heart sections, which were photographed using an Olympus SZX16. Dimensions were measured by placing lines 
in pictures of five CK2α−/− and WT heart pairs and analyzed using the Wilcoxon rank sum test. Heart sections 
from four to six somite paired CK2α−/− and WT embryos were stained with Hematoxylin-eosin (H&E) as 
described in57.
Immunofluorescence (IF) and whole mount immunofluorescence (WIF). WIF for phospho-histone 
H3/Ser10 (phH3) was performed in three somite-paired WT and CK2α−/− embryos as described in14. PhH3 IF 
staining in sections, was performed in slides with comparable sections from three somite-paired CK2α−/− and 
WT embryos. Slides were processed in parallel throughout the procedure as described in14. Fluorescent cells in 
the photographs were counted using ImageJ (NIH, Bethesda, MD, USA). Mitotic index was calculated as the 
percentage of phH3-positive cells/total number of cells (i.e. DAPI-stained cells, Invitrogen, Carlsbad, CA, USA) 
and were analyzed with a Wilcoxon rank sum test. Slides were mounted with ProLong Gold (Molecular Probes, 
Eugene, OR, USA) and photographed in a Nikon Eclipse TE-2000E/Photometrics CoolSnapHQ2 camera with 
NIS-elements software. For MCM3 and MCM4 immunofluorescence, slides with comparable sections from two 
somite-paired CK2α−/− and WT embryos were processed in parallel throughout all the procedures. 10% rabbit 
serum and 10% goat serum were used to block for MCM3 and MCM4, respectively, and no retrieving was per-
formed for either anti-MCM antibody. Sections were incubated with antibodies overnight at 4 °C. As negative 
controls, in one section of each slide no primary antibody was added, and in another neither primary nor sec-
ondary antibodies were added. Photographs were taken at the same magnification and exposure time, and were 
analyzed using ImageJ (NIH, USA). The number of stained cells was calculated in percentage as the number of 
antibody-stained positive cells/ total number of cells (DAPI), and significance analyzed with the Exact Wilcoxon 
test. To determine the percent of high- and low-intensity stained cells, the threshold set in ImageJ was applied for 
both WT and KO sections. For immunofluorescence quantitation, histograms represent mean values +/− stand-
ard deviation (STDEV). Statistical analysis was performed with R Statistical package (R Foundation for Statistical 
Computing, Vienna, Austria; Version 2.15.1). P-values < 0.05 were considered significant.
All applied methods were performed in accordance with the relevant guidelines and regulations.
Data Availability
RNA-seq data have been deposited in the ArrayExpress database at EMBL-EBI under accession number E-MTAB- 
8067.
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